Theralase Technologies Inc

TTX

Company Profile

  • Business description

    Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.

  • Contact

    41 Hollinger Road
    TorontoONM4B 3G4
    CAN

    T: +1 416 699-5273

    E: [email protected]

    https://www.theralase.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    31 December 2026

    Employees

    16

Stocks News & Analysis

stocks

ASX energy giant undervalued despite commissioning challenges

Near-term hurdles, long-term upside.
stocks

Undervalued ASX share upgrades guidance

Market share gains drive earnings upgrade despite a weak US housing backdrop.
stocks

ASX major bank drives strong quarterly profit

Profit momentum remains robust yet shares overvalued.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,112.0079.700.88%
CAC 408,433.2827.220.32%
DAX 4025,434.0373.000.29%
Dow JONES (US)52,210.08262.830.51%
FTSE 10010,848.5066.750.62%
HKSE25,310.85103.670.41%
NASDAQ24,932.0843.74-0.18%
Nikkei 22562,364.922,566.27-3.95%
NZX 50 Index13,861.9311.240.08%
S&P 5007,413.181.200.02%
S&P/ASX 2008,947.8085.600.97%
SSE Composite Index3,813.3144.93-1.16%

Market Movers